

Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan

Uppsala, Sweden – 18 July, 2023 – The Annual General Meeting of Biotage AB (publ) (“Biotage”) resolved on June 4, 2020 to adopt a long-term incentive plan (“LTIP 2020”) which has now expired and for this reason, a total of 52,347 ordinary shares are transferred free of charge to the participants in LTIP 2020. To cover tax costs associated with LTIP 2020, some participants intend to sell a number of shares through Danske Bank A/S on Nasdaq Stockholm and, correspondingly, the company transfers a maximum of 17,960 ordinary shares to cover social contribution costs associated with LTIP 2020 which is expected to take place during the period 18 July 2023 until 24 July 2023, at a price within the registered price range at the relevant time. In order to enable the transfer of own ordinary shares, the Board of Directors has resolved to reclassify 70,307 class C shares into ordinary shares in accordance with the reclassification provision in the company’s Articles of Association.

The company’s holding of own class C shares previously amounted to 729,817. Following the conversion of 70,307 class C shares and transfer of the corresponding number of ordinary shares, Biotage will hold 659,510 own class C shares.

This information was submitted for publication, through the agency of the contact persons set out above, at 13.00 CEST on 18 July 2023.

Website: www.biotage.com

Contacts

Tomas Blomquist, President and CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com

About Biotage

Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs appr. 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm. Website: www.biotage.com

Attachments

[Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan](#)